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Abstract  
Although hypercoagulable states are most often associated with venous thromboses, arterial thromboses are reported in 
protein C, protein S, antithrombin deficient patients and in those with factor V Leiden, components of hereditary thrombophilia. Because 
these arterial thromboses (peripheral artery disease, myocardial infarction, and cerebral infarction) mostly affect young persons, aged 
below 45 years, it is important to test and treat these thrombophilic defects. Because the relation thrombophilia – arterial thromboses is 
still under debate, due to conflicting data, this article is a review of studies published in literature regarding the implication of the above-
mentioned thrombophilic defects in cerebral infarcts. 
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Introduction  
Most patients with arterial stroke have diabetes, 
hypertension, hyperlipidemia, smoking or valvular heart 
disease as underlying risk factors. When such risk factors 
are absent, one should suspect hypercoagulable states 
as causative. The inherited hypercoagulable syndromes 
primarily affect veins and only rarely cause arterial 
thrombosis. The predilection to venous as opposed to 
arterial stroke may be partly due to the differing 
mechanisms of thrombosis on the venous and arterial 
sides of the circulation and within various organs. Stasis 
is a major predisposing factor in venous circulation 
whereas endothelial damage is a more important 
predisposing factor in arterial circulation. Because there 
are still conflicting data regarding the implications of 
protein C, protein S, antithrombin deficiencies and factor 
V Leiden mutation in arterial stroke, the present article is 
a review of the published studies debating this issue.  
Regarding the cerebral infarctions, the 
implications of protein S, C, and antithrombin deficiencies 
is still on debate; more certain is the implication of factor 
V Leiden.  
Half of the ischemic strokes are unexplained by 
conventional risk factors and the genetic predisposition 
has been deemed responsible for some of these risks. 
(Table 1) shows the monogenic causes of ischemic 
stroke.   
 
 
 
Disorders  Gene/chromosomal 
location responsible 
Small vessel disease   
    CADASIL  notch 3 gene 
    CARASIL  Unknown 
Cerebroretinal vasculopathy and HERNS  3p21.1–21.3 
Large artery disease   
    Dyslipidaemias  Various 
    Moyamoya disease  3p24.2–26 and 17q25 
    Pseudoxanthoma elasticum  ABCC6 gene 
    Neurofibromatosis type I  NFI gene 
Disorders affecting both small and large arteries   
    Fabry disease  α-galactosidase A gene 
    Homocystinuria  cystathione ß synthase gene 
Table 1  Monogenic causes for ischemic stroke [1]  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010  
  236 
© 2010, Carol Davila University Foundation
    Sickle cell disease  Methylene tetrahydrofolate reductase 
Cardioembolic   
    Cardiomyopathies: primary/secondary  Various 
    Familial dysrythmias  Various 
Prothrombotic disorders   
    Protein C, S deficiency  Protein C gene – 2q13-q14 chromosome 
Protein S gene – 3p11.1-3q11.2 chromosome 
    Antithrombin III deficiency  Antithrombin III gene– 1q23-25 chromosome 
    Familial anticardiolipin syndrome  Unknown 
    Activated protein C resistance  Factor V Leiden mutation G1691A mutation in factor V 
gene – 1q21-25 chromosome 
Arterial dissection   
    Ehlers-Danlos syndrome type IV  collagen type III gene 
    Fibromuscular dysplasia  Unknown 
    Marfan syndrome  fibrillin-1 gene 
Mitochondrial disorders   
    MELAS  Mitochondrial DNA mutations 
 
CADASIL, cerebral autosomal dominant 
arteriopathy with subcortical infarcts and 
leucoencephalopathy; CARASIL, cerebral autosomal 
recessive arteriopathy with subcortical infarcts and 
leucoencephalopathy; HERNS, hereditary 
endotheliopathy with retinopathy, nephropathy, and 
stroke; MELAS; mitochondrial myopathy, encephalopathy, 
lactic acidosis, and stroke like episodes;  
Stroke means different pathological processes, 
all of them having as an end point the focal cerebral 
ischemia. 85% of the strokes are ischemic and 15% 
hemorrhagic. Even among the patients with ischemic 
stroke, a number of pathologically different processes are 
responsible, as cardioembolism, large artery disease with 
arteriolosclerosis and thromboembolism, and small artery 
disease. The physiopathological mechanisms and the 
genetic influences responsible could be different for 
different stroke subtypes. Two family studies showed an 
association with large artery and small artery strokes, but 
not with cardioembolic stroke [2,3]. The association was 
stronger in cases of stroke in young age. In one study 
regarding the role of factor V Leiden mutation and 
ischemic stroke subtypes, it was proven that it is 
statistically significant more frequently in patients with 
large infarctions (13.6%; p < 0.025; OR 2.25, CI 1.16-
4.34) than in those without stroke (6.5%), therefore this 
mutation may predispose the person to large cerebral 
infarction. It has not been proved that it is a risk factor for 
ischemic stroke in general [4]. 
The prevalence of protein C, S and antithrombin 
III in ischemic stroke varies up to 23% in different studies 
[5].    
In an ample meta-analysis published in 2003, 
reports of cases and studies regarding the deficiencies of 
proteins S, C, antithrombin, and factor V Leiden in 
ischemic strokes were mentioned [6]. Protein C deficiency 
has occasionally been associated with arterial ischemic 
stroke [7]. The meta-analysis mentions reports of cases 
and studies that had a frequency of 4%, 5%, 6%, 11% 
and even 21% in the groups of stroke patients, depending 
on the admission criteria. These patients had strokes at a 
younger age than those without protein C deficiency. One 
study in which only one of the 329 patients aged between 
15 and 45 years had protein C deficiency is mentioned. 
The conclusion of the meta-analysis was that it appears 
that protein C deficiency is weakly associated with the 
arterial stroke [6].  
Protein S deficiency has been associated with 
cerebral arterial ischemia more often than has protein C 
deficiency. However, conflicting reports limit the reliability 
of this association. The meta-analysis describes case-
reports and studies published until 2003 regarding this 
subject: they reported a frequency of this deficiency of 
13,8% (5/36), 19% (8/35), 23% (19/98) in patients aged 
less than 45 years and  6% (4/66) in patients aged less 
than 60 years [6]. In this last study, all protein S deficiency 
patients had elevated anticardiolipin antibodies. This 
study suggests an association between antiphospholipidic 
syndrome and protein S deficiency in ischemic stroke 
patients. Conversely, numerous studies show a less 
frequent association of stroke and protein S deficiency 
(Table 2). In the Iowa cohort study, only 1 of the 329 
stroke patients aged between 15 and 45 years had 
protein S deficiency. A Swedish study of 107 patients 
aged between 18 and 44 years found only one with 
protein S deficiency [6] .  
 
 
 
Coagulopathy  Association with  
arterial stroke 
Protein C deficiency  weak 
Protein S deficiency  moderate 
Antithrombin III deficiency  rare 
Factor V Leiden mutation  moderate 
Prothrombin gene mutation  moderate 
Hyperhomocysteinemia  moderate 
Dysfibrinogenemia  rare 
Plasminogen deficiency  rare 
Sickle cell anemia  common 
Antiphospholipid antibodies  common 
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Antithrombin deficiency has only rarely been 
associated with stroke. The meta-analysis presents case-
reports and studies regarding the association of this 
deficiency with stroke. Different studies show frequencies 
of 5% (3/66), 8% (5/60), but there were studies that 
reported just one case of the 36 or 329 cases studied. It is 
worth mentioning that all studies included patients aged 
less than 45-55 years, and the study that reported a 
frequency of 5%, all antithrombin deficiency patients had 
suffered carotid artery territory strokes [6]. Thus, the 
evidence linking antithrombin deficiency with arterial 
stroke is weak. 
The factor V Leiden mutation, the cause of 
activated protein C resistance (in 90% of cases) is the 
most common inherited coagulopathy associated with 
stroke. The meta-analysis reports a prevalence of the 
mutation of 10% (3/30), 12,3%(10/81), according to 
different studies and 2 studies that included stroke 
patients aged younger than 45 years with cryptogenic 
cerebral ischemia found a prevalence of 12% and 15,9%, 
respectively[6]. 
In 2004, a meta-analysis of all the studies made 
until January 2003, was published in English-language 
journals and it was related to the investigation of any 
candidate gene for ischemic stroke in humans. In order to 
maintain genetic homogeneity, only studies in white adults 
were included. Data from 120 case-control studies were 
included. Pooled odds ratios with 95% confidence 
intervals (CIs) were included. Of the 32 genes studied, 15 
polymorphisms were identified. Statistically significant 
associations with ischemic stroke were identified only for 
factor V Leiden Arg506Gln (OR, 1.33; 95% CI, 1.12-1.58), 
but not for the other 3 deficits [8]. 
A study performed in Turkey and published in 
2005, studied 29 children with ischemic stroke and 20 
with intracerebral hemorrhage, all of whom were 
compared with 20 controls. The authors found no 
evidence of an association between factor V Leiden 
mutation and ischemic stroke or intracerebral 
hemorrhage. The conclusion was that factor V Leiden 
mutation did not seem to be associated with a risk of 
cerebrovascular disease [9]. Another study performed in 
the same country, published in 2007 had retrospectively 
assessed the risk factors of children with arterial stroke. It 
was proven that among the 31 patients, 2 had factor V 
Leiden, 2 protein C deficit, 2 antithrombin deficit and one 
protein S deficit. This study concluded that for the correct 
etiologic identification, prothrombotic  risk factors should 
be extensively evaluated in patients with arterial ischemic 
stroke [10]. A study performed in Italy and published in 
2008, regarding peri-neonatal ischemic stroke in a group 
of 24 children, found inherited thrombophilia (factor V 
Leiden mutation, prothrombin gene mutation and proteins 
C, S and antithrombin deficiencies) in 28,6% cases. 
Inherited thrombophilia was significantly more prevalent in 
patients with bad neurologic outcome (Fisher's exact test 
P = 0.002) [11].  
The risk of a stroke is high for persons with 
factor V Leiden combined with other vascular risk factors, 
such as smoking and contraceptive use. A study 
investigated the prevalence of these mutations  in 468 
patients with an acute stroke or transient ischemic attack 
(TIA) before the age of 60 and in a healthy control 
population  individually matched for age and gender. A 
significant  interaction between the factor V Leiden, 
smoking, and risk of stroke in women was found: female 
smokers without the factor V Leiden had a somewhat 
increased risk  of stroke of 2.6 (95% CI, 1.5 to 4.6; 
P=0.001) compared with nonsmoking non-carriers of the 
factor V Leiden. No such interaction was observed in men 
[12]. 
Nowadays, there are many studies about the 
association between patent foramen ovale and 
thrombophilic defects that lead to a high incidence of 
ischemic strokes, especially in young persons. 
Patent foramen ovale (PFO) is present in  25% 
of the general population, but in most cases, it does not 
affect health. But, this anomaly represents a possible 
cause of ischemic embolic neurological events in young 
patients [13,14]. The relation between patent foramen 
ovale and cryptogenic thromboembolic cerebral events 
has not been established and the suggested mechanisms 
are complex, including the paradoxical embolism from the 
periferic venous system, embolisms from thrombs formed 
in atrial septum and because of the transitory atrial 
arrhythmias [15]. It is believed that prothrombotic 
mutations are genetic risk factors for cryptogenic ischemic 
cerebrovascular events in young subjects with patent 
foramen ovale and there is an association between young 
patients with PFO and the risk of cerebral ischemia 
[16,17,18]. 
One study that included 97 young patients with 
PFO and 160 age-matched control subjects found that the 
combination  of either factor V Leiden or prothrombin 
G20210A and PFO was associated with a 4.7-fold (95% 
CI=1.4 to 16.1; P=0.008) increased  risk of cerebral 
ischemia in young patients. No statistically significant 
association was found for protein C, S or antithrombin 
deficiency [19]. Of the inherited thrombophilias, factor V 
Leiden and the prothrombin 20210 mutation have been 
associated with stroke, but this association is statistically 
significant only in children and adults under the age of 40. 
The risk of stroke in persons with these mutations is 
substantially increased by concomitant exposure to oral 
contraceptives [20]. In another study published in 2009 in 
Thrombosis and Haemostasis, that analyzed data from six 
eligible studies regarding the association of factor V 
Leiden with PFO, a trend toward an association for the 
FV(G1691A) mutation (OR 1.18; 95% CI 0.73 to 1.90, 
compared to control subjects was noticed; OR 1.14; 95% 
CI 0.62 to 2.09, compared to non-PFO-associated stroke 
patients). The status of carrier of FV(G1691A) mutation 
was associated with a risk for stroke of 1.98 (95% CI 1.38 
to 2.83) and 1.62 (95% CI 1.03 to 2.57), as compared to  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010  
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control subjects and non-PFO-associated stroke patients, 
respectively. Additional common prothrombotic genetic 
variants to standard initial screening may contribute to 
ranging PFO-associated stroke patients according to a 
different risk of ischemic events and targeting secondary 
prevention strategies [21].  
It was presumed that the presence of inherited 
thrombophilic defects could induce the potential risks and 
reduce the benefits of percutaneous closure of patent 
foramen ovale [22]. A study that investigated 72 patients 
with recurrent brain ischemia concluded that for 
cryptogenic stroke patients the association between PFO 
and thrombophilia significantly raises the risk for 
recurrences and percutaneous closure of patent foramen 
ovale is efficient in order to prevent recurrences in 
patients with thrombophilia [23]. 
Conclusions 
Dealing with a case of cerebral infarction with 
few risk factors for arteriosclerosis, the screening for 
thrombophilia should be made, especially when patients 
are aged below 45 years, have a personal history of 
recurrent thrombosis without precipitating factors, 
thrombosis in unusual sites, thrombosis during 
pregnancy, a positive family history of thrombosis. A 
positive result asks for initiation of the adequate 
anticoagulant treatment. 
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